On October 9, Moderna, Inc. rose 3.96% in regular trading, trading at $204.81/share, with Turnover of $2.5 billion. The stock's advance coincided with its official inclusion in the Nasdaq-100 Index at the open, triggering passive index fund demand.

Supporting sentiment, Tempus announced an expanded multi-year collaboration with Moderna and Merck to provide tumor tissue, blood sample collection, sequencing, and next-generation sequencing services for the individualized cancer therapy intismeran autogene. This reinforces the commercial pathway for the therapy being studied with Keytruda in melanoma and other cancers. Morgan Stanley had also raised its price target to $95 from $89.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)